Incannex Healthcare Limited American Depositary Shares (IXHL) is a publicly traded Healthcare sector company. As of May 21, 2026, IXHL trades at $3.70 with a market cap of $45.35M and a P/E ratio of -2.74. IXHL moved +0.81% today. Year to date, IXHL is -68.78%; over the trailing twelve months it is -48.47%. Its 52-week range spans $2.40 to $93.60. Rallies surfaces IXHL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Incannex Launches DReAMzz Trial Across 14 Sites to Optimize IHL-42X Dosing: Incannex Healthcare has activated infrastructure at all 14 clinical sites and begun the DReAMzz crossover dose optimization trial of IHL-42X in obstructive sleep apnea. The study follows positive Phase II RePOSA results, aims to refine dosing profiles and streamline Phase III design while leveraging FDA Fast Track designation.
| Metric | Value |
|---|---|
| Price | $3.70 |
| Market Cap | $45.35M |
| P/E Ratio | -2.74 |
| EPS | $-1.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.60 |
| 52-Week Low | $2.40 |
| Volume | 651 |
| Avg Volume | 0 |
| Revenue (TTM) | $86.00K |
| Net Income | $-46.88M |
| Gross Margin | 0.00% |
IXHL analyst coverage data. Average price target: $0.00.